Uprifosbuvir
- Generic Name
- Uprifosbuvir
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C22H29ClN3O9P
- CAS Number
- 1496551-77-9
- Unique Ingredient Identifier
- JW31KPS26S
- Background
Uprifosbuvir is under investigation in clinical trial NCT02332707 (Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Genotype (GT)1 and GT2 Infection (MK-3682-011)).
- Associated Conditions
- -
- Associated Therapies
- -
Efficacy and Safety of Uprifosbuvir (MK-3682) + Ruzasvir (MK-8408) in Treating Hepatitis C Virus Infection Genotypes 1-6 (MK-3682-041)
- First Posted Date
- 2016-11-06
- Last Posted Date
- 2021-02-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 282
- Registration Number
- NCT02956629
A Study of the Pharmacokinetics of Uprifosbuvir (MK-3682) and Ruzasvir (MK-8408) in Participants With Moderate and Severe Hepatic Insufficiency (MK-3682-029)
- First Posted Date
- 2016-01-28
- Last Posted Date
- 2018-09-17
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 24
- Registration Number
- NCT02666352
Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Genotype (GT)1 and GT2 Infection (MK-3682-011)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-01-07
- Last Posted Date
- 2019-07-23
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 443
- Registration Number
- NCT02332707
Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Virus (HCV) Genotype (GT) 3, GT4, GT5, and GT6 Infection (MK-3682-012)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-01-07
- Last Posted Date
- 2019-07-30
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 413
- Registration Number
- NCT02332720
Single and Multiple Dose Study of Uprifosbuvir (MK-3682/IDX21437) in Healthy and Hepatitis C Virus (HCV)-Infected Participants (MK-3682-001)
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-11-01
- Last Posted Date
- 2018-09-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 178
- Registration Number
- NCT01974687
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath